Trial Outcomes & Findings for Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation) (NCT NCT02839889)

NCT ID: NCT02839889

Last Updated: 2019-03-05

Results Overview

Change from baseline in mean daily NRS (Numerical Rating Scale) values will be calculated as the post-baseline value minus the baseline. Baseline NRS is the mean daily NRS values recorded during the Opioid Induced Constipation (OIC) Confirmation period. Numeric Rating Scale is 0-10. 0 is no pain and 10 is worst possible pain. Lower values are a better outcome and higher values are a worse outcome. Post-baseline values were calculated as the mean of NRS scores during visits 2-4.

Recruitment status

TERMINATED

Study phase

PHASE4

Target enrollment

12 participants

Primary outcome timeframe

Assessed from screening/Opioid Induced Constipation (OIC) Confirmation period through study completion, approximately 6 weeks.

Results posted on

2019-03-05

Participant Flow

This multi center was conducted at 3 sites in the US. Enrollment to the study was stopped due to recruitment challenges and no new patients have been screened as of January 2018. 5 patients were randomized across the 2 treatment groups.

To confirm eligibility participants underwent a 7 day baseline assessment/OIC confirmation period. 12 patients provided consent for this study, however 7 did not fulfill eligibility criteria during the 7 day baseline period.

Participant milestones

Participant milestones
Measure
Placebo
Placebo once daily for two weeks Placebo: Placebo once daily for two weeks, followed by two week open-label period
Naloxegol
Naloxegol 25mg tablets once daily for two weeks Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
Randomization Period
STARTED
2
3
Randomization Period
COMPLETED
2
3
Randomization Period
NOT COMPLETED
0
0
Open-Label Period
STARTED
0
5
Open-Label Period
COMPLETED
0
4
Open-Label Period
NOT COMPLETED
0
1

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Placebo
n=2 Participants
Placebo once daily for two weeks Placebo: Placebo once daily for two weeks, followed by two week open-label period
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
Total
n=5 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Age, Categorical
Between 18 and 65 years
1 Participants
n=99 Participants
1 Participants
n=107 Participants
2 Participants
n=206 Participants
Age, Categorical
>=65 years
1 Participants
n=99 Participants
2 Participants
n=107 Participants
3 Participants
n=206 Participants
Sex: Female, Male
Female
1 Participants
n=99 Participants
1 Participants
n=107 Participants
2 Participants
n=206 Participants
Sex: Female, Male
Male
1 Participants
n=99 Participants
2 Participants
n=107 Participants
3 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Asian
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
1 Participants
n=99 Participants
1 Participants
n=107 Participants
2 Participants
n=206 Participants
Race (NIH/OMB)
White
1 Participants
n=99 Participants
2 Participants
n=107 Participants
3 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Region of Enrollment
United States
2 participants
n=99 Participants
3 participants
n=107 Participants
5 participants
n=206 Participants
Baseline Numerical Rating Scale (NRS) for Pain
5.7 score on a scale
n=99 Participants
6.2 score on a scale
n=107 Participants
6.0 score on a scale
n=206 Participants
Baseline Electrocardiogram QTC Interval
430.8 Milliseconds
n=99 Participants
414.5 Milliseconds
n=107 Participants
421 Milliseconds
n=206 Participants
Baseline Electrocardiogram Heart Rate
82 beats per minute
n=99 Participants
79 beats per minute
n=107 Participants
80.2 beats per minute
n=206 Participants
Baseline Daily Opioid Use
300 morphine milligram equivalents per day
n=99 Participants
126.5 morphine milligram equivalents per day
n=107 Participants
196 morphine milligram equivalents per day
n=206 Participants
Baseline Systolic Blood Pressure
133.5 mmHg
n=99 Participants
118 mmHg
n=107 Participants
124.2 mmHg
n=206 Participants
Baseline Diastolic Blood Pressure
85 mmHg
n=99 Participants
71.3 mmHg
n=107 Participants
76.8 mmHg
n=206 Participants
Baseline Pulse Rate
81 beats per minute
n=99 Participants
79 beats per minute
n=107 Participants
79.8 beats per minute
n=206 Participants
Baseline Bristol Stool Scale score
3.91 score on a scale
n=99 Participants
1.94 score on a scale
n=107 Participants
2.73 score on a scale
n=206 Participants
Baseline Respiratory Rate
14 breaths per minute
n=99 Participants
15.3 breaths per minute
n=107 Participants
14.8 breaths per minute
n=206 Participants
Baseline Degree of Straining
2.21 score on a scale
n=99 Participants
2.06 score on a scale
n=107 Participants
2.12 score on a scale
n=206 Participants
Baseline Complete Evacuation with Bowel Movements
39.3 % of days with complete evacuation
n=99 Participants
41.7 % of days with complete evacuation
n=107 Participants
40.7 % of days with complete evacuation
n=206 Participants
Baseline Patient Assessment of Constipation Symptom Assessments (PAC-SYM)
Abdominal symptoms
6.5 score on a scale
n=99 Participants
8 score on a scale
n=107 Participants
7.4 score on a scale
n=206 Participants
Baseline Patient Assessment of Constipation Symptom Assessments (PAC-SYM)
Rectal Symptoms
2 score on a scale
n=99 Participants
3.3 score on a scale
n=107 Participants
2.8 score on a scale
n=206 Participants
Baseline Patient Assessment of Constipation Symptom Assessments (PAC-SYM)
Stool symptoms
7.5 score on a scale
n=99 Participants
8 score on a scale
n=107 Participants
7.8 score on a scale
n=206 Participants
Baseline Patient Assessment of Constipation Symptom Assessments (PAC-SYM)
Total Score
16 score on a scale
n=99 Participants
19.3 score on a scale
n=107 Participants
18 score on a scale
n=206 Participants
Baseline Patient Assessment of Constipation (PAC-QOL)
Physical Discomfort
8 score on a scale
n=99 Participants
4.7 score on a scale
n=107 Participants
6 score on a scale
n=206 Participants
Baseline Patient Assessment of Constipation (PAC-QOL)
Psychosocial discomfort
14 score on a scale
n=99 Participants
4.3 score on a scale
n=107 Participants
8.2 score on a scale
n=206 Participants
Baseline Patient Assessment of Constipation (PAC-QOL)
Worries/concerns
17 score on a scale
n=99 Participants
15.3 score on a scale
n=107 Participants
16 score on a scale
n=206 Participants
Baseline Patient Assessment of Constipation (PAC-QOL)
Satisfaction
5.5 score on a scale
n=99 Participants
3.3 score on a scale
n=107 Participants
4.2 score on a scale
n=206 Participants
Baseline Patient Assessment of Constipation (PAC-QOL)
Total Score
44.5 score on a scale
n=99 Participants
27.7 score on a scale
n=107 Participants
34.4 score on a scale
n=206 Participants

PRIMARY outcome

Timeframe: Assessed from screening/Opioid Induced Constipation (OIC) Confirmation period through study completion, approximately 6 weeks.

Change from baseline in mean daily NRS (Numerical Rating Scale) values will be calculated as the post-baseline value minus the baseline. Baseline NRS is the mean daily NRS values recorded during the Opioid Induced Constipation (OIC) Confirmation period. Numeric Rating Scale is 0-10. 0 is no pain and 10 is worst possible pain. Lower values are a better outcome and higher values are a worse outcome. Post-baseline values were calculated as the mean of NRS scores during visits 2-4.

Outcome measures

Outcome measures
Measure
Placebo
n=2 Participants
Placebo once daily for two weeks Placebo: Placebo once daily for two weeks, followed by two week open-label period
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
Numerical Rating Scale (NRS) for Pain Change From Baseline
0.65 score on a scale
Interval 0.3 to 1.0
.33 score on a scale
Interval -0.4 to 1.4

PRIMARY outcome

Timeframe: Assessed from screening through study completion, approximately 6 weeks.

Change from baseline in mean daily opioid dose will be calculated as the post-baseline value minus the baseline value. Positive changes from baseline indicate there was a need to increase the opioid dose. Baseline daily opioid dose is the mean daily opioid dose recorded during the Opioid Induced Constipation (OIC) Confirmation period.

Outcome measures

Outcome measures
Measure
Placebo
n=2 Participants
Placebo once daily for two weeks Placebo: Placebo once daily for two weeks, followed by two week open-label period
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
Daily Opioid Use Change From Baseline
1144 morphine milligram equivalents per day
Interval 0.0 to 2288.0
20 morphine milligram equivalents per day
Interval 0.0 to 60.0

PRIMARY outcome

Timeframe: Change from Baseline at End of Double Blind Phase (Visit 3, approximately day 15)

Population: All abnormal lab values were deemed not clinically significant by Investigators. Therefore, changes did not meet the criteria for an adverse event and changes were not collected.

Changes from Baseline to Visit 3 (approximately Day 15) for all patients will be calculated as the post-baseline test value minus the baseline test value.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: Change from Baseline at End of Double Blind Phase (Visit 3, approximately day 15)

Changes from Baseline to Visit 3 (approximately Day 15) for Electrocardiogram (ECG) QTC interval data will be derived by subtracting the baseline value from the final assessment data.

Outcome measures

Outcome measures
Measure
Placebo
n=2 Participants
Placebo once daily for two weeks Placebo: Placebo once daily for two weeks, followed by two week open-label period
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
Electrocardiogram QTC Interval
-24.8 milliseconds
Interval -61.6 to 12.0
-6.9 milliseconds
Interval -17.0 to 4.0

PRIMARY outcome

Timeframe: Change from Baseline at End of Double Blind Phase (Visit 3, approximately day 15)

Changes from Baseline to Visit 3 (approximately Day 15) for Electrocardiogram (ECG) heart rate data will be derived by subtracting the baseline value from the final assessment data.

Outcome measures

Outcome measures
Measure
Placebo
n=2 Participants
Placebo once daily for two weeks Placebo: Placebo once daily for two weeks, followed by two week open-label period
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
Electrocardiogram Heart Rate
9 beats per minute
Interval 7.0 to 11.0
10 beats per minute
Interval 2.0 to 23.0

PRIMARY outcome

Timeframe: Change from Baseline in systolic blood pressure through study completion, approximately 6 weeks.

Change from Baseline in systolic blood pressure at post baseline (visits 2, 3, 4) will be derived as the value at the visit minus the baseline value for the same assessment. The post-baseline values were calculated as a mean of values from visits 2 through 4.

Outcome measures

Outcome measures
Measure
Placebo
n=2 Participants
Placebo once daily for two weeks Placebo: Placebo once daily for two weeks, followed by two week open-label period
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
Change From Baseline in Systolic Blood Pressure
-10.3 mmHg
Interval -30.3 to 9.7
-8.8 mmHg
Interval -19.0 to 7.3

PRIMARY outcome

Timeframe: Change from Baseline in diastolic blood pressure through study completion, approximately 6 weeks.

Change from Baseline in diastolic blood pressure at post baseline (visits 2, 3, 4) will be derived as the value at the visit minus the baseline value for the same assessment. The post-baseline values were calculated as a mean of values from visits 2 through 4.

Outcome measures

Outcome measures
Measure
Placebo
n=2 Participants
Placebo once daily for two weeks Placebo: Placebo once daily for two weeks, followed by two week open-label period
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
Change From Baseline in Diastolic Blood Pressure
-10.5 mmHg
Interval -20.0 to -1.0
-1.8 mmHg
Interval -9.3 to 4.0

PRIMARY outcome

Timeframe: Change from Baseline in respiratory rate through study completion, approximately 6 weeks.

Change from Baseline in respiratory rate at post baseline (visits 2, 3, 4) will be derived as the value at the visit minus the baseline value for the same assessment. The post-baseline values were calculated as a mean of values from visits 2 through 4.

Outcome measures

Outcome measures
Measure
Placebo
n=2 Participants
Placebo once daily for two weeks Placebo: Placebo once daily for two weeks, followed by two week open-label period
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
Change From Baseline in Respiratory Rate
1.7 breaths per minute
Interval -2.0 to 5.3
1.2 breaths per minute
Interval -0.7 to 3.7

PRIMARY outcome

Timeframe: Change from Baseline in pulse rate through study completion, approximately 6 weeks.

Change from Baseline in pulse rate at post baseline (visits 2, 3, 4) will be derived as the value at the visit minus the baseline value for the same assessment. The post-baseline values were calculated as a mean of values from visits 2 through 4.

Outcome measures

Outcome measures
Measure
Placebo
n=2 Participants
Placebo once daily for two weeks Placebo: Placebo once daily for two weeks, followed by two week open-label period
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
Change From Baseline in Pulse Rate
4.5 beats per minute
Interval 3.7 to 5.3
10.3 beats per minute
Interval 5.3 to 15.3

SECONDARY outcome

Timeframe: Assessed from Baseline through Study Completion, approximately 6 weeks.

Daily diary data will be used to identify RFBMs. The weekly RFBM frequency within each time period will be calculated as: (Total number of RFBMs during the time period of interest/number of days) x 7. RFBM rate calculated from post baseline period.

Outcome measures

Outcome measures
Measure
Placebo
n=2 Participants
Placebo once daily for two weeks Placebo: Placebo once daily for two weeks, followed by two week open-label period
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
Rescue Free Bowel Movements (RFBM) Responder Rate
8.14 RFBMs/days *7
Interval 3.5 to 12.79
3.82 RFBMs/days *7
Interval 1.59 to 5.55

SECONDARY outcome

Timeframe: First dose date to first post-dose rescue free bowel movement

Time (in hours) to first post-dose rescue free bowel movement minus first dose date and time.

Outcome measures

Outcome measures
Measure
Placebo
n=2 Participants
Placebo once daily for two weeks Placebo: Placebo once daily for two weeks, followed by two week open-label period
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
Time to First Post-dose Rescue Free Laxation
23.3 Hours
Interval 17.96 to 28.58
33.5 Hours
Interval 3.67 to 67.73

SECONDARY outcome

Timeframe: Assessed from baseline through Study Completion, approximately 6 weeks.

The Bristol Stool Scale classifies the type of bowel movement on a scale from 1-7, based on the appearance of stool. 1 indicates severe constipation, 2 indicates mild constipation, 3-4 indicate a normal bowel movement, 5 indicates that the patient is lacking dietary fiber, 6 indicates mild diarrhea, and 7 indicates severe diarrhea. A better score would trend toward the middle of the scale (ranges 3-4), while scores at either end of the scale correspond to worse outcomes. Bristol Stool Scale (BSS) Score calculated by the sum of daily BSS scores divided by the number of bowel movements that occurred from baseline to study completion. Change from Baseline calculated as the Baseline value minus the post-baseline value.

Outcome measures

Outcome measures
Measure
Placebo
n=2 Participants
Placebo once daily for two weeks Placebo: Placebo once daily for two weeks, followed by two week open-label period
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
Bristol Stool Scale (BSS) Score
-.06 score on a scale
Interval -0.4 to 0.28
2.37 score on a scale
Interval 1.51 to 3.02

SECONDARY outcome

Timeframe: day 1, day 15, day 29

The PAC-SYM is divided into three subscales. Each item is scored 0-4. Items 1-4 measure abdominal symptoms (total subscale range 0-16), items 5-7 measure rectal symptoms (total subscale score 0-12), and items 8-12 measure stool symptoms (total subscale range 0-20). For each subscale, lower scores are better and higher scores are worse. The total construct score is generated by summing the scores of the subscales. This total score ranges from 0-48, with lower scores corresponding to better outcomes, and higher scores corresponding to worse outcomes. Change from baseline in mean values calculated as post-baseline value minus baseline value for each scale, and for total. Post-baseline values defined as the mean of day 15 and day 29.

Outcome measures

Outcome measures
Measure
Placebo
n=2 Participants
Placebo once daily for two weeks Placebo: Placebo once daily for two weeks, followed by two week open-label period
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
Patient Assessment of Constipation Symptoms (PAC-SYM)
Abdominal Symptoms
1 score on a scale
Interval 0.0 to 2.0
.5 score on a scale
Interval -2.0 to 3.0
Patient Assessment of Constipation Symptoms (PAC-SYM)
Rectal Symptoms
1.25 score on a scale
Interval 1.0 to 1.5
1.2 score on a scale
Interval -1.5 to 5.0
Patient Assessment of Constipation Symptoms (PAC-SYM)
Stool Symptoms
.5 score on a scale
Interval -0.5 to 1.5
-.2 score on a scale
Interval -1.5 to 1.5
Patient Assessment of Constipation Symptoms (PAC-SYM)
Total Score
2.75 score on a scale
Interval 2.5 to 3.0
1.5 score on a scale
Interval -3.5 to 9.5

SECONDARY outcome

Timeframe: day 1, day 15, day 29

The PAC-QOL is a 28-item questionnaire divided into 4 subscales. Items 1-4 measure physical discomfort (subscale range 0-16), 5-12 measure psychosocial discomfort (range 0-32), 13-23 measure worries/concerns (range 0-44), and 24-28 measure satisfaction (range 0-20). For each subscale, lower scores are better and higher scores are worse. The total score is generated by summing the scores of the subscales. This total score ranges from 0-112, with lower scores corresponding to better outcomes, and higher scores corresponding to worse outcomes. Change from baseline in mean values calculated as post-baseline value minus baseline value for each subscale, and for total. Post-baseline values defined as the mean of day 15 and day 29.

Outcome measures

Outcome measures
Measure
Placebo
n=2 Participants
Placebo once daily for two weeks Placebo: Placebo once daily for two weeks, followed by two week open-label period
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
Patient Assessment of Constipation Quality of Life (PAC-QOL)
Physical discomfort
-1.25 score on a scale
Interval -1.5 to -1.0
0.17 score on a scale
Interval 0.0 to 0.5
Patient Assessment of Constipation Quality of Life (PAC-QOL)
Psychosocial Discomfort
-1 score on a scale
Interval -9.0 to 7.0
6 score on a scale
Interval 1.0 to 14.0
Patient Assessment of Constipation Quality of Life (PAC-QOL)
Worries/concerns
1.5 score on a scale
Interval -3.5 to 6.5
1.17 score on a scale
Interval -1.5 to 3.5
Patient Assessment of Constipation Quality of Life (PAC-QOL)
Satisfaction
3.5 score on a scale
Interval 2.0 to 5.0
3.83 score on a scale
Interval 2.0 to 6.5
Patient Assessment of Constipation Quality of Life (PAC-QOL)
Total Score
2.75 score on a scale
Interval -12.0 to 17.5
11.17 score on a scale
Interval 5.5 to 20.0

SECONDARY outcome

Timeframe: Assessed at baseline through Study Completion with each bowel movement, approximately 6 weeks.

Degree of straining scale is 1 to 5 with 1 being "not at all" and 5 being "an extreme amount". Lower scores are better and higher scores are worse. Change from baseline in mean values calculated as the post baseline value minus the baseline. Degree of Straining scale change from baseline mean scores calculated from baseline to study completion.

Outcome measures

Outcome measures
Measure
Placebo
n=2 Participants
Placebo once daily for two weeks Placebo: Placebo once daily for two weeks, followed by two week open-label period
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
Degree of Straining Question With Each Bowel Movement
.6 score on a scale
Interval -0.31 to 1.5
-.35 score on a scale
Interval -0.67 to 0.09

SECONDARY outcome

Timeframe: Assessed at baseline through Study Completion with each bowel movement, approximately 6 weeks.

Change from Baseline in mean values calculated as the post baseline value minus the baseline. The post baseline value is the percentage of days from baseline to study completion with at least one complete bowel evacuation.

Outcome measures

Outcome measures
Measure
Placebo
n=2 Participants
Placebo once daily for two weeks Placebo: Placebo once daily for two weeks, followed by two week open-label period
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
Complete Evacuation Question With Each Bowel Movement
21.92 % of days with complete evacuation
Interval 21.43 to 22.41
7.7 % of days with complete evacuation
Interval -11.36 to 79.31

Adverse Events

Placebo

Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths

Naloxegol

Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Placebo
n=2 participants at risk
Placebo once daily for two weeks Placebo: Placebo once daily for two weeks, followed by two week open-label period
Naloxegol
n=3 participants at risk
Naloxegol 25mg tablets once daily for two weeks Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
Gastrointestinal disorders
Nausea
50.0%
1/2 • Number of events 2 • Occurrences from Baseline through study completion, approximately 6 weeks
0.00%
0/3 • Occurrences from Baseline through study completion, approximately 6 weeks
Gastrointestinal disorders
Gastroesophageal reflux disease
50.0%
1/2 • Number of events 1 • Occurrences from Baseline through study completion, approximately 6 weeks
0.00%
0/3 • Occurrences from Baseline through study completion, approximately 6 weeks
General disorders
fever
50.0%
1/2 • Number of events 1 • Occurrences from Baseline through study completion, approximately 6 weeks
0.00%
0/3 • Occurrences from Baseline through study completion, approximately 6 weeks
General disorders
chills
50.0%
1/2 • Number of events 1 • Occurrences from Baseline through study completion, approximately 6 weeks
0.00%
0/3 • Occurrences from Baseline through study completion, approximately 6 weeks
Gastrointestinal disorders
diarrhea
100.0%
2/2 • Number of events 2 • Occurrences from Baseline through study completion, approximately 6 weeks
0.00%
0/3 • Occurrences from Baseline through study completion, approximately 6 weeks
General disorders
abdominal distention
50.0%
1/2 • Number of events 1 • Occurrences from Baseline through study completion, approximately 6 weeks
0.00%
0/3 • Occurrences from Baseline through study completion, approximately 6 weeks
Renal and urinary disorders
bladder spasms
0.00%
0/2 • Occurrences from Baseline through study completion, approximately 6 weeks
33.3%
1/3 • Number of events 1 • Occurrences from Baseline through study completion, approximately 6 weeks
Musculoskeletal and connective tissue disorders
increased back pain
0.00%
0/2 • Occurrences from Baseline through study completion, approximately 6 weeks
33.3%
1/3 • Number of events 1 • Occurrences from Baseline through study completion, approximately 6 weeks
General disorders
increased abdominal pain
0.00%
0/2 • Occurrences from Baseline through study completion, approximately 6 weeks
33.3%
1/3 • Number of events 1 • Occurrences from Baseline through study completion, approximately 6 weeks
Gastrointestinal disorders
worsening constipation
0.00%
0/2 • Occurrences from Baseline through study completion, approximately 6 weeks
33.3%
1/3 • Number of events 1 • Occurrences from Baseline through study completion, approximately 6 weeks
Nervous system disorders
mental status changes
0.00%
0/2 • Occurrences from Baseline through study completion, approximately 6 weeks
33.3%
1/3 • Number of events 1 • Occurrences from Baseline through study completion, approximately 6 weeks
Gastrointestinal disorders
abdominal cramping
0.00%
0/2 • Occurrences from Baseline through study completion, approximately 6 weeks
33.3%
1/3 • Number of events 1 • Occurrences from Baseline through study completion, approximately 6 weeks

Additional Information

Janet Bull, MD

Four Seasons Compassion for Life

Phone: 8286926178

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: LTE60